2024
Amygdala Cannabinoid 1 Receptor, Pain Response, and Emotional Numbing in Trauma-Exposed Individuals
Korem N, Hillmer A, D’Souza D, Nia A, Levy I, Pietrzak R, Harpaz-Rotem I. Amygdala Cannabinoid 1 Receptor, Pain Response, and Emotional Numbing in Trauma-Exposed Individuals. JAMA Network Open 2024, 7: e2432387. PMID: 39250156, PMCID: PMC11385051, DOI: 10.1001/jamanetworkopen.2024.32387.Peer-Reviewed Original Research
2022
Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users
Johnson E, Colbert S, Jeffries P, Tillman R, Bigdeli T, Karcher N, Chan G, Kuperman S, Meyers J, Nurnberger J, Plawecki M, Degenhardt L, Martin N, Kamarajan C, Schuckit M, Murray R, Dick D, Edenberg H, D’Souza D, Di Forti M, Porjesz B, Nelson E, Agrawal A. Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. Schizophrenia Bulletin 2022, 49: 778-787. PMID: 36545904, PMCID: PMC10154717, DOI: 10.1093/schbul/sbac196.Peer-Reviewed Original ResearchConceptsCannabis useAlcohol use disorderCognitive difficultiesSchizophrenia polygenic risk scoresFirst cannabis useDaily cannabis useCannabis usersSocial withdrawalUnusual experiencesCannabis involvementPolygenic risk scoresExpected directionGenetic riskUse disordersIndependent replication sampleLike experiencesGenetic liabilityCannabisSchizophreniaPolygenic riskPolygenic liabilityReplication sampleExperienceAnalytic sampleDisordersConsensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
D’Souza D, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal Of Biological Psychiatry 2022, 23: 719-742. PMID: 35315315, DOI: 10.1080/15622975.2022.2038797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWFSBP Task ForceRisk of psychosisAge of exposureRates of psychosisRecurrent psychosisTask ForceEndocannabinoid systemPsychosis outcomesConsensus paperHigh riskPsychotic disordersPsychotic statesPsychosisPotency of cannabisCriteria of causalityCannabisCannabinoidsLines of evidenceCannabis lawsRiskExposureDisordersEvidenceConfoundersIllness
2021
Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia
Ranganathan M, Rahman M, Ganesh S, D’Souza D, Skosnik PD, Radhakrishnan R, Pathania S, Mohanakumar T. Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia. The World Journal Of Biological Psychiatry 2021, 23: 33-45. PMID: 33821753, DOI: 10.1080/15622975.2021.1907720.Peer-Reviewed Original ResearchConceptsHealthy controlsSex-matched healthy controlsBlood-brain barrierNovel peripheral biomarkersPlasma-derived exosomesAstroglial pathologyWestern blot analysisPeripheral biomarkersSynaptophysin levelsBrain barrierPeripheral signatureAstrocytic pathologyGFAP concentrationsSchizophrenia patientsExosomal protein expressionNeuropsychiatric disordersNeurodegenerative disordersProtein immunopositivitySchizophreniaProtein expressionGroup differencesDisordersPatientsScarce dataConcentration of exosomes
2018
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reports
2015
The early identification of psychosis: can lessons be learnt from cardiac stress testing?
Gupta S, Ranganathan M, D’Souza D. The early identification of psychosis: can lessons be learnt from cardiac stress testing? Psychopharmacology 2015, 233: 19-37. PMID: 26566609, PMCID: PMC4703558, DOI: 10.1007/s00213-015-4143-3.Peer-Reviewed Original ResearchConceptsCardiac stress testingCoronary artery diseaseMyocardial infarctionOutcome measuresPsychotic disordersDetection of CADManagement of schizophreniaStress testingManagement of anginaDiagnosis of schizophreniaStress testArtery diseasePsychotic episodePsychiatric disordersPredictive valueEarly identificationEarly detectionSchizophreniaPsychosisDisordersTarget populationRiskSafe stimuliRange of risksUrgent need
2014
Gone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan R, Wilkinson ST, D’Souza D. Gone to Pot – A Review of the Association between Cannabis and Psychosis. Frontiers In Psychiatry 2014, 5: 54. PMID: 24904437, PMCID: PMC4033190, DOI: 10.3389/fpsyt.2014.00054.BooksPsychotic disordersFamily historyEmergence of psychosisPolymorphisms of COMTPublic health policySymptoms of schizophreniaTrigger relapsePsychosis outcomesHigh riskEpidemiological studiesAcute exposurePsychotomimetic symptomsPsychophysiological abnormalitiesPersistent effectsCognitive deficitsCannabis useHealth policyCannabinoidsSymptomsGenetic factorsCannabisChildhood traumaDisordersStandard criteriaWarrants serious considerationImpact of Cannabis Use on the Development of Psychotic Disorders
Wilkinson ST, Radhakrishnan R, D’Souza D. Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports 2014, 1: 115-128. PMID: 25767748, PMCID: PMC4352721, DOI: 10.1007/s40429-014-0018-7.BooksAcute psychosisPsychotic disordersCannabis useAcute intoxicationPersistent psychotic disordersLater psychotic disorderPersistence of psychosisPersistent psychosisHealthy volunteersCognitive symptomsCannabis intoxicationCannabinoid usePsychosisVulnerable populationsComponent causesCannabisIntoxicationGenetic vulnerabilityDose responseSynthetic cannabinoidsChildhood abuseDisordersCannabinoidsPotential riskMore researchChapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis
Radhakrishnan R, Addy P, Sewell R, Skosnik P, Ranganathan M, D’Souza D. Chapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis. 2014, 423-474. DOI: 10.1016/b978-0-12-418679-8.00014-9.Peer-Reviewed Original ResearchPsychotic disordersCannabis exposureComponent causesCannabinoid receptor functionDevelopment of schizophreniaHeavy cannabis exposurePublic health policyCannabinoid exposureTrigger relapsePsychophysiological deficitsCognitive symptomsReceptor functionSchizophreniaHealth policyCannabinoidsPsychosisCannabisLines of evidenceDisordersFurther studiesSymptomsBiological mechanismsExposureIndividual vulnerabilityCause
2012
Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment
Addy P, Radhakrishnan R, Cortes J, D’Souza D. Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment. FOCUS The Journal Of Lifelong Learning In Psychiatry 2012, 10: 140-153. DOI: 10.1176/appi.focus.10.2.140.Peer-Reviewed Original ResearchComorbid substance use disorderSubstance use disordersUse disordersSubstance abuseHigh rateTreatment of schizophreniaCo-occurring disordersCourse of schizophreniaCocaine use disorderSelf-medication hypothesisCombination pharmacotherapyComorbid alcoholService utilizationLow compliancePatientsSchizophreniaSubstance useDisordersTreatmentDSM definitionCliniciansEpidemiologyThorough assessmentCannabisLatest findings
2010
Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia
Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Brazilian Journal Of Psychiatry 2010, 32: 515-530. PMID: 20512267, DOI: 10.1590/s1516-44462010000500005.Peer-Reviewed Original ResearchConceptsPsychotic disordersCannabis exposureComponent causesCannabinoid receptor functionCauses of schizophreniaHeavy cannabis exposurePublic health policyCannabinoid exposureTrigger relapsePsychophysiological deficitsCognitive symptomsReceptor functionSchizophreniaHealth policyCannabinoidsLines of evidenceDisordersFurther studiesCannabisSymptomsPsychosisBiological mechanismsExposureIndividual vulnerabilityCause
2009
Cannabis and psychosis/schizophrenia: human studies
D’Souza D, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives Of Psychiatry And Clinical Neuroscience 2009, 259: 413-431. PMID: 19609589, PMCID: PMC2864503, DOI: 10.1007/s00406-009-0024-2.Peer-Reviewed Original ResearchConceptsPsychotic disordersRole of cannabinoidsPsychosis/schizophreniaTransient psychotic symptomsComponent causesCannabinoid receptor functionCauses of schizophreniaWarrants further studyDuration of exposureCannabinoid exposureTrigger relapsePsychotic illnessPsychotic symptomsGeneral populationCognitive symptomsHealthy individualsHuman studiesReceptor functionCannabis useNeurodevelopmental processesCannabinoidsFirst exposureSymptomsDisordersGenetic factorsNeuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2006
Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorder
Srihari VH, Lee TS, Rohrbaugh RM, D'Souza DC. Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorder. Schizophrenia Research 2006, 82: 261-264. PMID: 16442782, DOI: 10.1016/j.schres.2005.11.022.Peer-Reviewed Original ResearchConceptsPsychotic disordersCycloid psychosisTransient psychotic disordersICD-10 categoriesIV-TR criteriaMinimal functional impairmentFavorable prognosisRecurrent psychosisUnknown incidenceDistinct pathophysiologyFunctional impairmentClinical attentionPsychosisDisordersFurther investigationPrognosisPathophysiologyIncidenceCasesImpairment
2004
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004, 29: 1558-1572. PMID: 15173844, DOI: 10.1038/sj.npp.1300496.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyArousalAttentionBehaviorCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolFemaleHallucinogensHemodynamicsHumansHydrocortisoneInjections, IntravenousMaleMemory, Short-TermMental RecallPanicProlactinPsychiatric Status Rating ScalesPsychometricsPsychoses, Substance-InducedSpeechVerbal LearningConceptsCannabinoid receptor functionWord recallRecognition recallVerbal fluencyCognitive deficitsProspective safety dataNegative symptomsAbuse disordersHealthy individualsCounterbalanced studyMonths poststudyRecallPsychotomimetic effectsPsychotic disordersReceptor functionPsychosisEndogenous psychosesIndividualsDistractibilityFluencyTransient symptomsDisordersEndocrine effectsSafety dataAnxiety
2001
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.Peer-Reviewed Original ResearchPsychopharmacological challenge studies in psychiatric research
D'Souza D, Krystal J. Psychopharmacological challenge studies in psychiatric research. International Review Of Psychiatry 2001, 13: 40-46. DOI: 10.1080/09540260123077.Peer-Reviewed Original Research
1999
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disorders